Chen L, Chen X, Cai G, Jiang H, Chen X, Zhang M
MedComm (2020). 2024; 5(11):e783.
PMID: 39492831
PMC: 11531656.
DOI: 10.1002/mco2.783.
Wendt R, Sobhani A, Diefenhardt P, Trappe M, Volker L
Biomedicines. 2024; 12(10).
PMID: 39457572
PMC: 11504437.
DOI: 10.3390/biomedicines12102259.
Song J, Ke B, Tu W, Fang X
Ren Fail. 2023; 45(2):2259228.
PMID: 37755331
PMC: 10538460.
DOI: 10.1080/0886022X.2023.2259228.
Rajasekaran A, Green T, Renfrow M, Julian B, Novak J, Rizk D
Drugs. 2023; 83(16):1475-1499.
PMID: 37747686
PMC: 10807511.
DOI: 10.1007/s40265-023-01940-2.
Tesar V, Radhakrishnan J, Charu V, Barratt J
Kidney Int Rep. 2023; 8(9):1730-1740.
PMID: 37705895
PMC: 10496078.
DOI: 10.1016/j.ekir.2023.06.010.
A bibliometric analysis of complement in IgA nephropathy from 1991 to 2022.
Guo Y, Zhang H, Yu X
Front Pharmacol. 2023; 14:1200193.
PMID: 37576817
PMC: 10414182.
DOI: 10.3389/fphar.2023.1200193.
Renal-Protective Roles of Lipoic Acid in Kidney Disease.
Kamt S, Liu J, Yan L
Nutrients. 2023; 15(7).
PMID: 37049574
PMC: 10097220.
DOI: 10.3390/nu15071732.
Urinary complement profile in IgA nephropathy and its correlation with the clinical and pathological characteristics.
Wang D, Wu C, Chen S, Li Y, Wang L, Zhang Y
Front Immunol. 2023; 14:1117995.
PMID: 37020564
PMC: 10068869.
DOI: 10.3389/fimmu.2023.1117995.
Proteomic profiling of IgA nephropathy reveals distinct molecular prognostic subtypes.
Chen X, Li M, Zhu S, Lu Y, Duan S, Wang X
iScience. 2023; 26(3):105961.
PMID: 36879796
PMC: 9984961.
DOI: 10.1016/j.isci.2023.105961.
Comparative proteomic analysis of children FSGS FFPE tissues.
Ni J, Tian S, Bai L, Lv Q, Liu J, Liu J
BMC Pediatr. 2022; 22(1):707.
PMID: 36503536
PMC: 9743561.
DOI: 10.1186/s12887-022-03764-7.
Functional variant rs12614 in confers a low risk of IgA nephropathy by attenuating complement alternative pathway activation in Han Chinese.
Shi D, Feng S, Zhong Z, Cai L, Wang M, Fu D
Front Immunol. 2022; 13:973169.
PMID: 36311737
PMC: 9606215.
DOI: 10.3389/fimmu.2022.973169.
Associations between Biomarkers of Complement Activation, Galactose-Deficient IgA1 Antibody and the Updated Oxford Pathology Classification of IgA Nephropathy.
Juan Y, Chiang W, Lin W, Yang C, Chou S, Hung R
J Clin Med. 2022; 11(14).
PMID: 35887995
PMC: 9323307.
DOI: 10.3390/jcm11144231.
Urinary C5b-9 as a Prognostic Marker in IgA Nephropathy.
Yu B, Park J, Lee K, Oh Y, Choi S, Kim J
J Clin Med. 2022; 11(3).
PMID: 35160271
PMC: 8836759.
DOI: 10.3390/jcm11030820.
The Glomerulus According to the Mesangium.
Ebefors K, Bergwall L, Nystrom J
Front Med (Lausanne). 2022; 8:740527.
PMID: 35155460
PMC: 8825785.
DOI: 10.3389/fmed.2021.740527.
Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment.
Knoppova B, Reily C, King R, Julian B, Novak J, Green T
J Clin Med. 2021; 10(19).
PMID: 34640530
PMC: 8509647.
DOI: 10.3390/jcm10194501.
Complement Activation Is Associated With Crescents in IgA Nephropathy.
Wang Z, Xie X, Li J, Zhang X, He J, Wang M
Front Immunol. 2021; 12:676919.
PMID: 34594322
PMC: 8477028.
DOI: 10.3389/fimmu.2021.676919.
An Update on the Current State of Management and Clinical Trials for IgA Nephropathy.
Cheung C, Rajasekaran A, Barratt J, Rizk D
J Clin Med. 2021; 10(11).
PMID: 34200024
PMC: 8200196.
DOI: 10.3390/jcm10112493.
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.
Garred P, Tenner A, Mollnes T
Pharmacol Rev. 2021; 73(2):792-827.
PMID: 33687995
PMC: 7956994.
DOI: 10.1124/pharmrev.120.000072.
Integrated Fecal Microbiome and Serum Metabolomics Analysis Reveals Abnormal Changes in Rats with Immunoglobulin A Nephropathy and the Intervention Effect of Zhen Wu Tang.
Li J, Cao Y, Lu R, Li H, Pang Y, Fu H
Front Pharmacol. 2021; 11:606689.
PMID: 33584283
PMC: 7872959.
DOI: 10.3389/fphar.2020.606689.
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.
Anliker-Ort M, Dingemanse J, van den Anker J, Kaufmann P
Front Immunol. 2020; 11:599417.
PMID: 33362783
PMC: 7758461.
DOI: 10.3389/fimmu.2020.599417.
